Results 41 to 50 of about 33,513 (195)
Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley +1 more source
IntroductionGut microbiota plays a key role in drug metabolism. While gut microbiota dysbiosis is known to contribute to hypertension pathogenesis, its impact on drug metabolism remains poorly considered.
Jiaxuan Xia +11 more
doaj +1 more source
Losartan, an AT1 angiotensin II (ANG II) receptor non-peptide antagonist, induces an increase in mean arterial pressure (MAP) when injected intracerebroventricularly (icv) into rats.
A.M. Sugawara +5 more
doaj +1 more source
The endothelial-to-mesenchymal transition (EMT) of glomerular vascular endothelial cells is considered to be pivotal in diabetic nephropathy (DN).
Yufeng Yao +5 more
doaj +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Losartan-induced hepatic injury
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare.
Ozaras, Reşat +7 more
core +1 more source
Pharmacokinetic interaction of drugs, the metabolisable cytochrome P450 isoenzyme CYP2C9
The role of cytochrome P450 isoforms CYP2C9 and in the metabolism of losartan described. Losartan pharmacokinetics data in humans and laboratory animals are presented.
O. G. Gribakina +4 more
doaj
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
Background. The study of drugs' possible metabolic and biological interactions in preclinical models is a necessary condition for improving the development of most combinations of medicines. Objective.
Larysa Bondarenko +3 more
doaj +1 more source
Introduction: There is an urgent need for health authorities across Europe to fully realise potential savings from increased use of generics to sustain their healthcare systems.
James eMoon +12 more
doaj +1 more source

